Evidence map›Paper›PMID 36395695›Full record

Trial reportMaturitas2023

Associations between pituitary-ovarian hormones and cognition in recently menopausal women independent of type of hormone therapy.

Juliana M Kling, N Maritza Dowling, Heather Bimonte-Nelson, Carey E Gleason, Kejal Kantarci, Cynthia M Stonnington, S Mitch Harman, Frederick Naftolin, Lubna Pal, Marcelle Cedars and 4 more

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Maturitas, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00154180 phase4unknown statusnot on this map

Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women

TypeinterventionalSponsorKronos Longevity Research InstituteRan2005 to 2012Enrolled728ConditionsMenopause, ArteriosclerosisArmsConjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
NCT00623311 no registry record found
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 1 country.

Juliana M KlingDivision of Women's Health Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA. Electronic address: kling.juliana@mayo.edu.
N Maritza DowlingDepartment of Acute & Chronic Care, School of Nursing, Department of Epidemiology & Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.
Heather Bimonte-NelsonDepartment of Psychology, Arizona State University, Tempe, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ 85006, USA.
Carey E GleasonDivision of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health and the Wisconsin Alzheimer's Disease Research Center, Madison VA GRECC, Madison, WI, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Cynthia M StonningtonDepartment of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ, USA.
S Mitch HarmanPhoenix VA Health Care System, Phoenix, AZ, USA.
Frederick Naftoline-Bio Corp., New York, NY, USA.
Lubna PalDepartment of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.
Marcelle CedarsDepartment of Obstetrics and Gynecology, University of California San Francisco School of Medicine, San Francisco, CA, USA.
JoAnn E MansonDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Taryn T JamesSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Eliot A BrintonUtah Lipid Center, Salt Lake City, UT, USA.
Virginia M MillerDepartment of Surgery, Mayo Clinic, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, USA.
Mayo Clinic in Arizona · USArizona State University · USBrigham and Women's Hospital · USGeriatric Research Education and Clinical Center · USLouisville Metabolic and Atherosclerosis Research Center · USMayo Clinic in Florida · USMilken Institute · USPhoenix VA Health Care System · USUniversity of California, San Francisco · USUniversity of Wisconsin–Madison · USYale University · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
MAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4M
YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI HEATHER Allyson BIMONTE-NELSON · 2021 to 2026
$24.9M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CHAPPELL, RICHARD J · 2009 to 2018
$16.2M
Prevention of Alzheimer's disease in women: risks and benefits of hormone therapyRF1AG057547 · NIA · MAYO CLINIC ROCHESTER · PI GLEASON, CAREY E, KANTARCI, KEJAL · 2017 to 2020
$11.1M
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseU54AG044170 · NIA · MAYO CLINIC ROCHESTER · PI KANTARCI, KEJAL, MIELKE, MICHELLE M · 2018 to 2022
$7.7M
Variations in Hormone Therapy: Effects on Cognition and Markers of Brain AgingR01AG028084 · NIA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI BIMONTE-NELSON, HEATHER ALLYSON · 2007 to 2022
$4.7M
Estrogen, Platelets, and ArtherosclerosisR01HL090639 · NHLBI · MAYO CLINIC ROCHESTER · PI BAILEY, KENT R, MILLER, VIRGINIA M · 2008 to 2012
$1.9M
NCATS NIH HHS UL1 TR001863NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1 RR024150NHLBI NIH HHS R01 HL090639NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG028084NIA NIH HHS RF1 AG057547NIA NIH HHS U54 AG044170
6 · The paper itself

Abstract

objectivesTo examine associations of pituitary-ovarian hormone levels with cognition before and after different formulations of hormone therapy (HT) or placebo independent of treatment group.

methodsRecently menopausal, healthy women were randomized to 0.45 mg/day oral conjugated equine estrogens (o-CEE, n = 109), 50 μg/day transdermal 17β (tE2, n = 107) or placebo pills and patches (n = 146); women on active treatment received oral 200 mg/day micronized progesterone for 12 days per month. Levels of estrone, 17β-estradiol, follicle stimulating hormone, luteinizing hormone, androstenedione, and testosterone were determined prior to and after 48 months of study participation. Neuropsychological testing was administered at baseline, and months 18, 36 and 48. Latent growth curve models controlling for education level, age, APOE allele status, waist circumference, and treatment examined the trajectories of each cognitive domain after accounting for the effect of hormone levels at baseline and months 18, 36 and 48. A linear multivariate mixed model examined the effect of changes in hormone levels on changes in trajectories of complex attention tasks with varying degrees of difficulty.

resultsAll women were adherent to treatment at month 48. Higher baseline estrone levels were associated with poorer global cognition, auditory attention and working memory, visual attention, and executive function, but not working memory. Higher levels of baseline 17β-E2 were associated with poorer cognitive performance, with marginal significance at baseline in speeded language and mental flexibility (p = 0.013). Other hormone levels were not associated with cognition. Controlling for all treatments, hormone levels at baseline and at month 48 did not have any significant correlation with cognitive trajectories over time. SUMMARY: In healthy, recently menopausal women, baseline estrone levels were inversely associated with selected cognitive factors independent of two types of HT or placebo during 4 years of follow-up. Baseline levels of the other pituitary-ovarian hormones studied were not associated with baseline cognition, nor were changes in any hormones associated with changes in cognition during the study. The marginal association between estradiol levels and cognitive factors warrants further investigation. CLINICALTRIALS: GOV NUMBERS: NCT00154180, NCT00623311.

Indexed as

EstroneMenopauseAnimalsCognitionEstradiolFemaleHorsesHumansPituitary HormonesEstradiolEstronePituitary HormonesCognitionMenopausal hormone therapyMenopausePituitary ovarian hormones

Identifiers

PMID36395695
PMCPMC10077876
OpenAlexW4307898902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.